Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company also develops antiviral therapies and vaccines, including Abivertinib, COVI-MSC, COVI-AMG, COVIDROPS, and COVI SHIELD; and diagnostic test solutions, such as COVISTIX, COVITRACK, and Virex. Its products are used for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases treatment. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023. Show more
Location: 4955 Directors Place, San Diego, CA, 92121, United States | Website: https://www.sorrentotherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
1.378M
52 Wk Range
$0.00 - $0.10
Previous Close
$0.00
Open
$0.00
Volume
87,225
Day Range
$0.00 - $0.00
Enterprise Value
135.5M
Cash
80.64M
Avg Qtr Burn
-58.66M
Insider Ownership
0.00%
Institutional Own.
0.03%
Qtr Updated
06/30/23
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
STI-5656 (Abivertinib Maleate) (BTK and EGFR inhibitor) Details Lung disease, Lung cancer, Non-small cell lung carcinoma, Cancer | Phase 3 Data readout | |
SP-102 (SEMDEXA™) Details Sciatica , Spine disorder | Phase 3 Update | |
OVYDSO (STI-1558) Details COVID-19 | Phase 3 Initiation | |
COVI-DROPS Details COVID-19 | Phase 2 Data readout | |
Phase 2 Data readout | ||
SP-103 Details Chronic lower back pain | Phase 2 Data readout | |
STI-1499 (COVIGUARD™) Details COVID-19 | Phase 1 Data readout | |
STI-3031 (anti-Pd-L1 antibody) Details Urothelial cancer, Cancer | Failed Discontinued | |
Abivertinib Maleate (Fujovee) (STI-5656) (BTK inhibitor) Details Solid tumor/s, Cancer, Prostate cancer, Castration-resistant prostate cancer | Failed Discontinued | |
Failed Discontinued | ||
STI-2020 (COVI-AMG) Details COVID-19, Solid tumor/s | Failed Discontinued | |
Failed Discontinued |
